Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer

Oncologist

Volumn 12, Issue 4, 2007, Pages 390-396

  Penault Llorca, Frédérique ^a,c   Abrial, Catherine ^a   Mouret Reynier, Marie Ange ^a,c   Raoelfils, Inès ^a   Durando, Xavier ^a,c   Leheurteur, Marianne ^a   Gimbergues, Pierre ^a,c   Tortochaux, Jacques ^a,c   Curé, Hervé ^a,b,c,d,e   Chollet, Philippe ^a,b,c,d  

^a CENTRE JEAN PERRIN   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d Centre d'Investigation Clinique   (France)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Breast cancer; HER 2; Pathological response

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; PARAFFIN; PIRARUBICIN; TRASTUZUMAB; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 34247850896     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-4-390     Document Type: Article

References (16)

1. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-3685.
2. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with Trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 2003;21:46-53.
3. Coudert BP, Arnould L, Moreau L et al. Pre-operative systemic (neoadjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: Results of a multicenter phase II trial. Ann Oncol 2006;17:409-414.
4. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223-228.
5. Abrial C, Mouret-Reynier MA, Amat S et al. Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers. Med Oncol 2005;22:233-240.
6. Amat S, Abrial C, Penault-Llorca F et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: A retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005;94:255-263.
7. Chollet P, Charrier S, Brain E et al. Clinical and pathological response to primary chemotherapy in inoperable breast cancer. Eur J Cancer 1997;33:862-866.
8. Van Praagh I, Curé H, Leduc B et al. Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. The Oncologist 2002;7:418-423.
9. Amat S, Bougnoux P, Penault-Llorca F et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breastconservation rate. Br J Cancer 2003;88:1339-1345.
10. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1957;53:457-471.
11. Curé H, Amat S, Penault-Llorca F et al. Prognostic value of residual node involvement in operable breast cancer after induction chemotherapy. Breast Cancer Res Treat 2002;76:37-45.
12. Chollet P, Amat S, Belembaogo E et al. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer 2003;89:1185-1191.
13. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353(16):1673-1684.
14. Perez EA, Suman VJ, Davidson N et al. NCCTG N9831 Update. Proc Am Soc Clin Oncol 2005;23:556:17.
15. Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-1672.
16. Penault-Llorca F, Cayre A, Bouchet-Mishellany F et al. Induction chemotherapy for breast carcinoma: Predictive markers and relation with outcome. Int J Oncol 2003;22:1319-1325.